SCHEMBL2395927

SCHEMBL2395927

NC(=O)Cc1ccc(F)cc1-c1cc(Cl)cc(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 0.42
ACLY P53396 1/20 0.41
ICMT O60725 7/20 0.40
CHRM3 P20309 4/20 0.40
CHRM2 P08172 1/20 0.40
CHRM1 P11229 1/20 0.40
AKR1C3 P42330 2/20 0.37
AKR1C2 P52895 2/20 0.37
CTSA P10619 1/20 0.36
MPO P05164 1/20 0.36
SLC6A4 P31645 1/20 0.36
AKR1C1 Q04828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890733 0.87 ICMT (0.44) ICMTCHRM3CHRM2CHRM1
SCHEMBL9890681 0.86 PTGDR2 (0.45) APPCHRM3CHRM2CHRM1AKR1C3
SCHEMBL9890766 0.84 ICMT (0.45) ICMTMPOSLC6A4
SCHEMBL16416508 0.82 GCGR (0.45) APPICMTCHRM3CHRM2CHRM1
SCHEMBL2394999 0.81 ICMT (0.46) ACLYICMT
SCHEMBL9890789 0.81 CHRM3 (0.40) APPCHRM3CHRM2CHRM1AKR1C3
SCHEMBL9890764 0.80 ICMT (0.54) ICMT
SCHEMBL2391279 0.80 CYP2C19 (0.48) APPACLYICMTCHRM3CHRM1
SCHEMBL2393365 0.79 CYP2C19 (0.43) APPACLYICMTCHRM3CHRM1
SCHEMBL1395757 0.77 ALDH1A1 (0.44) ICMTMPOSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US claimed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP claimed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US claimed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 APP 2725/4885ACLY 3939/4885ICMT 2894/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 APP 2725/4885ACLY 3939/4885ICMT 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.